NCT06832137尚未招募1 期
The Efficacy and Safety of CMTS4520 for Chronic Constipation in Adults： A Randomized, Double-Blind, Placebo-Controlled Trial.
The Second Hospital of Nanjing Medical University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2025年3月31日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- The clinical response rate after treatment
研究概览
简要总结
This is a randomized controlled trial to explore the efficacy and safety of CMTS4520 (Dietary Fiber Probiotics) for patients with chronic constipation.
详细描述
At least 100 subjects who meet all the inclusion criteria but do not meet any exclusion criteria will be enrolled in this study. They will be randomly assigned to the CMTS4520 group (dietary fiber probiotics capsules) and the control group (placebo). Data of demographic characteristics, intestinal symptoms, medicine treatment usage and clinical outcomes will be collected. After treatment, they will enter the follow-up period for efficacy and safety evaluation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Meet all of the following inclusion criteria :
- •Voluntary sign informed consent, age 18-70 years old (including the threshold), male and female.
- •For subjects diagnosed with chronic constipation, the duration of the disease is at least 6 months, and meet the following criteria:
- •Frequency of spontaneous defecation <3 times/week (spontaneous defecation refers to spontaneous defecation without the aid of remedial purgatives or manual assistance).
- •Dry and hard stool: More than a quarter of the stool is type 1 or 2 on the Bristol Fecal Trait Scale.
- •The subject or his/her legal representative has given informed consent, is fully aware of the purpose of the study, is able to communicate well with the investigator, and is able to understand and comply with the requirements of the study.
排除标准
- •All exclusion criteria below are not met:
- •Participants with outlet obstruction constipation, such as rectal mucosal prolapse.
- •Participants with a history of intestinal resection.
- •Participants with intestinal stenosis caused by organic lesions of the digestive tract (e.g., tumor, inflammation, anal fissures, Crohn's disease, ulcerative colitis, radiation enteritis, intestinal adhesions, intestinal tuberculosis) as confirmed by colonoscopy within the past 24 months.
- •Participants with constipation secondary to systemic diseases affecting the digestive tract, including:
- •Neurological diseases (e.g., Parkinson's disease, spinal cord injury, multiple sclerosis).
- •Muscle diseases (e.g., amyloidosis, dermatomyositis).
- •Psychiatric disorders or severe mood disorders (e.g., A Hospital Anxiety and Depression Scale score ≥15).
- •Opioid-induced constipation.
- •Poorly controlled metabolic diseases (e.g., thyroid dysfunction) or metabolic diseases with gastrointestinal complications (e.g., gastrointestinal autonomic dysfunction, diabetic gastroparesis).
- •Have a history of major surgery or severe trauma within 3 months and have not fully recovered.
- •Participants with any of the following cardiac abnormalities:
- •New York Heart Association (NYHA) Class III or higher heart failure.
- •Myocardial infarction or unstable angina within the past 6 months.
- •Prolonged QTc interval on electrocardiogram (≥450ms for males, ≥470ms for females).
- •Atrial arrhythmias that cannot be stably controlled by drugs and ventricular arrhythmias requiring pharmacological control (including grade 2 or higher atrioventricular block).
- •Participants with poor lung function, as assessed by the investigator, that may impact study treatment, such as acute chronic obstructive pulmonary disease(COPD) or those requring long-term oral, intravenous corticosteroids (excluding inhalant/spray formulations).
- •Uncontrolled immune diseases requring long-term systemic corticosteroid use (excluding topical use).
- •Participants with reproductive system disorders that may cause abdominal pain (e.g., ovarian cysts, endometriosis, primary dysmenorrhea).
- •Participants with significant laboratory abnormalities that, in the investigator's judgment, may affect safety or study completion, including:
- •Hemoglobin <100g/L.
- •Serum creatinine ≥1.5 times the upper limit of normal (ULN).
- •Abnormal liver function (AST>1.5×ULN, ALT>1.5×ULN or total bilirubin >1.5×ULN).
- •Clinically significant abnormalitieshe in routine stool tests or fecal occult blood indicating gastrointestinal lesions.
- •Participants with active hepatitis (requiring or undergoing long-term treatment), HIV, or active tuberculosis.
- •Participants with a history of drug or alcohol abuse (defined as consuming more than 14 standard drinks peer week: 1 standard drink= 360mL of beer, 45mL of 40% spirits, or 150mL of wine) or substance abuse.
- •Participants with known allergies or intolerances to the investigational drug, similar drugs or excipients.
- •Participants who have used anti-infective drugs (antibiotics, antifungals, antivirals) within 14 days prior to enrollment or require anti-infective treatment at the time of enrollment evaluation.
- •Participants who have used drugs or foods that regulate intestinal microbiota (e.g., bifidobacterium, probiotics, prebiotics, fermented milk, yogurt) within 2 weeks prior to screening or during the study.
- •Participants who have undergone hydrotherapy for bowel cleansing within one month prior to treatment.
- •Women who are pregnant, breastfeeding, or unwilling to use effective contraception for 3 months after the last dose of the study drug.
- •Participants who have participated in drug intervention clinical trials within 1 month prior to enrollment.
- •Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
结局指标
主要结局
The clinical response rate after treatment
时间窗: One-week post-CMTS4520 administration，Two-week post-CMTS4520 administration，Four-week post-CMTS4520 administration，Eight-week post-CMTS4520 administration
A clinical response was defined as a patient achieving complete spontaneous bowel movement (CSBM) at least 50% of the time after receiving CMTS4520. CSBM was defined as the number of spontaneous defecation with complete exhaust feeling without taking remedial purgative or manual assistance.
次要结局
- The incidence of treatment-related adverse events (AE) assessed by CTCAE, Version 5.0(Two-week post-CMTS4520 adminiatration, Four-week post-CMTS4520 administration，Eight-week post-CMTS4520 administration)
- The weekly usage rate of assisted defecation drugs.(One-week post-CMTS4520 administraion，Two-week post-CMTS4520 administraion, Four-week post-CMTS4520 administraion，Eight-week post-CMTS4520 administraion)
研究者
Faming Zhang
Professor, Gastroenterology
The Second Hospital of Nanjing Medical University
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Constipation in AdultsConstipationNCT06832176The Second Hospital of Nanjing Medical University100
尚未招募
1 期
Evaluate the Safety and Tolerability of SCT650C in Healthy VolunteersAutoimmune DiseaseNCT05894707Sinocelltech Ltd.32
已完成
3 期
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected PatientsHepatitis C, ChronicNCT01725529Janssen R&D Ireland457
已完成
不适用
Transcranial direct current stimulation (tDCS) combined with robotic rehabilitation for upper limbs in strokeMotor injuries of the upper limb and functional dependence in adults with strokeNervous System DiseasesISRCTN29077878niversity of Castile-La Mancha21
已完成
3 期
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)AutismNCT02410902Curemark190